Transarterial chemoembolization in Barcelona Clinic Liver Cancer Stage 0/A hepatocellular carcinoma.
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Heung Cheol | - |
dc.contributor.author | Suk, Ki Tae | - |
dc.contributor.author | Kim, Dong Joon | - |
dc.contributor.author | Yoon, Jai Hoon | - |
dc.contributor.author | Kim, Yeon Soo | - |
dc.contributor.author | Baik, Gwang Ho | - |
dc.contributor.author | Kim, Jin Bong | - |
dc.contributor.author | Kim, Chang Hoon | - |
dc.contributor.author | Sung, Hotaik | - |
dc.contributor.author | Choi, Jong Young | - |
dc.contributor.author | Han, Kwang Hyub | - |
dc.contributor.author | Park, Seung Ha | - |
dc.date.accessioned | 2022-07-16T06:18:23Z | - |
dc.date.available | 2022-07-16T06:18:23Z | - |
dc.date.created | 2021-05-13 | - |
dc.date.issued | 2014-01 | - |
dc.identifier.issn | 1007-9327 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/160824 | - |
dc.description.abstract | Aim: To evaluate the clinical characteristics of patients with Barcelona Clinic Liver Cancer (BCLC) stage 0 and A hepatocellular carcinoma (HCC) after transarterial chemoembolization (TACE). Methods: Between January 2001 and September 2011, 129 patients with BCLC stage 0 and stage A HCC who underwent TACE were retrospectively enrolled. Patient characteristics, routine computed tomography and TACE findings, survival time and 1-, 5-, and 10-year survival rates, risk factors for mortality, and survival rates according to the number of risk factors were assessed. Results: The mean size of HCC tumors was 2.4 ± 1.1 cm, and the mean number of TACE procedures performed was 2.5 ± 2.1. The mean overall survival time and 1-, 5-, and 10-year survival rates were 80.6 ± 4.9 mo and 91%, 63% and 49%, respectively. In the Cox regression analysis, a Child-Pugh score > 5 (P = 0.005, OR = 3.86), presence of arterio-venous shunt (P = 0.032, OR = 4.41), amount of lipiodol used (> 7 mL; P = 0.013, OR = 3.51), and female gender (P = 0.008, OR = 3.47) were risk factors for mortality. The 1-, 5-, and 10-year survival rates according to the number of risk factors present were 96%, 87% and 87% (no risk factors), 89%, 65%, and 35% (1 risk factor), 96%, 48% and unavailable (2 risk factors), and 63%, 17%, and 0% (3 risk factors), respectively (P < 0.001). Conclusion: TACE may be used as curative-intent therapy in patients with BCLC stage 0 and stage A HCC. The Child-Pugh score, arterio-venous shunt, amount of lipiodol used, and gender were related to mortality after TACE. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | W J G PRESS | - |
dc.title | Transarterial chemoembolization in Barcelona Clinic Liver Cancer Stage 0/A hepatocellular carcinoma. | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Yoon, Jai Hoon | - |
dc.identifier.doi | 10.3748/wjg.v20.i3.745 | - |
dc.identifier.scopusid | 2-s2.0-84892884968 | - |
dc.identifier.wosid | 000330856400014 | - |
dc.identifier.bibliographicCitation | WORLD JOURNAL OF GASTROENTEROLOGY, v.20, no.3, pp.745 - 754 | - |
dc.relation.isPartOf | WORLD JOURNAL OF GASTROENTEROLOGY | - |
dc.citation.title | WORLD JOURNAL OF GASTROENTEROLOGY | - |
dc.citation.volume | 20 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 745 | - |
dc.citation.endPage | 754 | - |
dc.type.rims | ART | - |
dc.type.docType | 정기학술지(Article(Perspective Article포함)) | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Gastroenterology & Hepatology | - |
dc.relation.journalWebOfScienceCategory | Gastroenterology & Hepatology | - |
dc.subject.keywordPlus | LONG-TERM SURVIVAL | - |
dc.subject.keywordPlus | HEPATITIS-C VIRUS | - |
dc.subject.keywordPlus | RADIOFREQUENCY ABLATION | - |
dc.subject.keywordPlus | PROGNOSTIC-FACTORS | - |
dc.subject.keywordPlus | RESECTION | - |
dc.subject.keywordPlus | TRANSPLANTATION | - |
dc.subject.keywordPlus | CIRRHOSIS | - |
dc.subject.keywordPlus | TRIALS | - |
dc.subject.keywordPlus | PREDICTORS | - |
dc.subject.keywordPlus | SYSTEMS | - |
dc.subject.keywordAuthor | Carcinoma | - |
dc.subject.keywordAuthor | Hepatocellular | - |
dc.subject.keywordAuthor | Chemoembolization | - |
dc.subject.keywordAuthor | Therapeutic | - |
dc.subject.keywordAuthor | Survival | - |
dc.subject.keywordAuthor | Stage | - |
dc.subject.keywordAuthor | Efficacy | - |
dc.identifier.url | https://www.wjgnet.com/1007-9327/full/v20/i3/745.htm | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.